Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22300997 | 0.84 | LOXL2 (0.47) | CYP11B2HRH3LOXL2CYP19A1 | |
| SCHEMBL22300400 | 0.84 | CYP2A6 (0.47) | CYP11B1CYP11B2HRH3LOXL2LMNA | |
| Hydrochloric Acid SCHEMBL18641507 | 0.83 | LOXL2 (0.46) | CYP11B2HRH3LOXL2CYP19A1 | |
| SCHEMBL4009961 | 0.81 | EPHX2 (0.64) | CYP11B1CYP11B2HRH3LOXL2EPHX2 | |
| SCHEMBL9267704 | 0.81 | HRH3 (0.43) | CYP11B1CYP11B2HRH3LOXL2EPHX2 | |
| SCHEMBL18667483 | 0.80 | CYP2C19 (0.39) | CYP11B1CYP11B2HRH3LOXL2CYP19A1 | |
| SCHEMBL1312626 | 0.77 | HSD17B10 (0.58) | CYP19A1CYP2A6 | |
| SCHEMBL21229041 | 0.76 | EGLN1 (0.44) | NAMPT | |
| SCHEMBL18641516 | 0.75 | MMP2 (0.40) | LMNA | |
| SCHEMBL22300549 | 0.75 | GAA (0.44) | CYP11B1CYP11B2HRH3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1898923-A1 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | Casper, Robert F. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | MOUNT SINAI HOSPITAL (CA) | 2008-02-21 | — | — | US | disclosed |
| WO-2002083240-A9 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING SA (CH) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004012728-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| EP-1383578-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003082254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AROMATASE INHIBITOR AND AN ESTROGEN SUITABLE FOR HORMONE REPLACEMENT THERAPY FOR A MALE | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082299-A1 | IMPROVED HORMONE REPLACEMENT THERAPY | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002083241-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083239-A1 | AROMATASE INHIBITORS FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-5378721-A | AROMATASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1995-01-03 | — | — | US | disclosed |
| US-5246952-A | Antitumor agents | CIBA-GEIGY CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | CYP19A1, SHBG, HSD17B11 | CYP11B1 69/4885CYP11B2 63/4885HRH3 4396/4885 |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP11B1 20/4885CYP11B2 25/4885HRH3 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.